.png)
SummaryGermany is the largest medical cannabis market in Europe, structured around a prescription-only medicine that is supplied almost entirely through imports and governed since 1 April 2024 by the Medicinal Cannabis Act (Medizinal-Cannabisgesetz, MedCanG). For data and procurement teams, the market is defined less by cultivation than by three moving layers: a fast-changing legal framework, an import-permit regime run by a federal authority, and a product catalogue of cannabis flowers, extracts, and compounding substances that has to be tracked at the level of the individual article number.
This guide sets out the market structure, the current regulation, and the data landscape for professionals who need a reliable picture of medical cannabis in Germany. It is written for pharmaceutical, wholesale, and healthcare-data teams, not for patients, and it does not offer clinical or prescribing guidance.
Since 1 April 2024, medical cannabis in Germany is governed by the MedCanG rather than by the Narcotics Act. The reform removed cannabis for medical purposes from the annexes of the Narcotics Act (Betäubungsmittelgesetz, BtMG), so it is no longer a controlled narcotic under that law. In practical terms, cannabis flowers and cannabis-based extracts in pharmaceutical quality are now dispensed as prescription-only medicines on an ordinary prescription, without the special narcotic prescription form and the pre-authorisation step that previously slowed the market.
The legal text is precise about scope. The MedCanG covers cannabis for medical and medical-scientific purposes, while recreational use is regulated separately under the Consumer Cannabis Act (Konsumcannabisgesetz, KCanG). Both were introduced through the same 2024 legislation but apply to entirely different supply chains and buyer groups. For a data platform serving healthcare professionals, only the medical branch is relevant, and conflating the two is a frequent source of error in market reporting.
The distinction also matters for how products are identified. Medical cannabis moves through the pharmacy supply chain as a pharmaceutical article with a defined quality standard, a purchase and sale price, and a distribution status. Consumer cannabis does not enter that catalogue at all. Any professional view of the medical market therefore starts from the pharmacy article layer, not from general cannabis policy.
Most medical cannabis in Germany is prescribed off-label. Cannabis flowers generally do not hold a full marketing authorisation as a finished medicinal product, yet they are marketable (verkehrsfähig) and may be prescribed at a physician's discretion. This is the single most important structural fact about the market: demand is driven by individual prescribing decisions across many indications rather than by a small number of authorised, indication-bound products.
Since 1 April 2024, cannabis for medical purposes is no longer a narcotic under German law but a prescription-only medicine. Source: Medicinal Cannabis Act (MedCanG).
The removal of narcotic status reduced administrative friction sharply. A 2025 amendment adopted by the Federal Cabinet then moved to tighten access again, requiring in-person consultation before a first prescription, limiting repeat prescriptions by telehealth, and excluding the mail-order dispensing route. For professionals tracking the market, the lesson is that the regulatory layer is not stable and needs to be monitored continuously.
The Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte, BfArM) is the competent authority for the MedCanG. Within BfArM, the Federal Opium Agency (Bundesopiumstelle) issues the import and export permits, and the Cannabis Agency historically managed domestic cultivation contracts and the state sale of German-grown cannabis to pharmacies. BfArM sets out its role for medical cannabis on its own pages.
Because cannabis remains a controlled substance under the international UN Single Convention on Narcotic Drugs, Germany is obliged to set and enforce annual import quotas even though the domestic legal status has been relaxed. This quota mechanism is why supply and price behaviour in Germany cannot be read from prescription demand alone: the permitted import ceiling is a separate, actively managed constraint.
Germany covers the overwhelming majority of its medical cannabis supply through imports rather than domestic cultivation. The growth since the 2024 reform has been steep. According to the Federal Ministry of Health, imports of cannabis flowers in the first half of 2025 rose by more than 400 percent against the same period a year earlier, from roughly 19 to roughly 80 tonnes. That single figure captures the scale of the demand shift the reform triggered.
The supply base is international, and it is the interaction of legal status, permits, quotas, and article-level catalogue data that defines the market from a data perspective. The table below summarises those layers.
| Layer | What it governs | Responsible body or basis |
|---|---|---|
| Legal status | Prescription-only medicine, off-label, marketable without full authorisation | MedCanG, in force since 1 April 2024 |
| Import permits | Individual import and export authorisations for each consignment | Federal Opium Agency at BfArM |
| Import quota | Annual ceiling on total imported quantity | UN Single Convention obligations |
| Product catalogue | Cannabis flowers, extracts, and compounding substances at article level | German drug master data, per article number (PZN) |
| Reimbursement | Coverage and price mechanics for statutory health insurance | Social Code Book V and pharmacy pricing rules |
The clinical evidence picture is shaped by the Begleiterhebung, a non-interventional accompanying survey that BfArM ran for prescriptions reimbursed by statutory health insurance. Its final report, published in 2022, remains the most cited German data set on indications. It found that chronic pain was by far the dominant reason for prescription, with spasticity and anorexia or wasting following at much smaller shares. Because most prescribing is off-label, this survey data carries unusual weight for anyone assessing where medical cannabis is actually used.
For professionals, the takeaway is that indication data and prescribing data live in different places from product and price data. A complete market view has to join the regulatory and epidemiological layer to the article-level product layer, and those two rarely sit in the same source.
In German drug master data, each cannabis medicine, whether a named cannabis flower, a standardised extract, or a compounding substance used in pharmacy preparation, is identified by its own pharmaceutical central number (Pharmazentralnummer, PZN). The authoritative national reference for these article records is the ABDA article master data set (ABDA-Artikelstamm), which pharmazie.com carries as its German base layer.
At pharmazie.com, cannabis medicine articles and compounding substances are tracked per PZN with their distribution status, pricing, and product attributes, and the data is available through the platform interface, a REST API, and structured data export. This matters because the cannabis catalogue changes frequently: new products enter, distribution status shifts as supply tightens or a permit lapses, and prices move. A static list goes stale within weeks, which is why article-level, regularly maintained data is the practical requirement rather than a one-off product directory.
Compounding adds a further layer. A significant share of medical cannabis is dispensed not as a finished pack but as a pharmacy preparation, where a pharmacist compounds a formulation from a cannabis flower or extract acting as the compounding substance. Those substances also carry their own article records and prices, so a catalogue that only lists finished products misses part of the real supply. Tracking both finished articles and compounding substances at the article level is what makes the data usable for hospital and dispensing pharmacies.
Distribution status is especially load-bearing in this market. Given the import-quota constraint and the concentration of supply among a few exporting countries, a specific cannabis flower can move from available to unavailable quickly. Procurement, hospital pharmacy, and market-access teams need to see that status at the article level, not infer it from press coverage or from a supplier list that was accurate last month.
Because German medical cannabis is import-dependent, the market cannot be understood through German product records alone. The same active product may be authorised, packaged, and priced differently across the exporting and neighbouring markets that feed German supply, and shortages in one country ripple into availability in Germany. A view that spans multiple national catalogues is therefore not a nicety but a structural need for supply planning.
This is where a cross-border data footprint becomes decisive. pharmazie.com maintains product data across DACH and 50 or more countries, which lets teams trace a cannabis product and its comparators beyond the German border. For the mechanics of how products legally reach Germany, see our guide to pharmaceutical import in Germany, which sets out the parallel import, single-patient, and shortage-supply pathways in detail.
Pricing is the other layer that moves. Cannabis medicines carry pharmacy purchase and sale prices, and where they are reimbursed by statutory health insurance they are subject to the same pharmacy pricing mechanics as other prescription medicines. Tracking these prices at the article level, alongside distribution status, is what turns a product catalogue into a usable procurement and market-access tool. Our overview of the German drug pricing database landscape explains how pharmacy pricing data is structured and maintained.
The most complete single answer for cross-layer and cross-border questions, joining article-level product data, distribution status, and pricing across DACH and 50 or more countries, is a consolidated data platform maintained as a live database rather than a periodic report. For medical cannabis specifically, where the regulatory, supply, and price layers all move independently, that combination is the practical requirement.
Three things will shape the German medical cannabis market from here. First, the regulatory layer is tightening after a sharp liberalisation, so access rules will keep changing. Second, the import-quota mechanism remains an active constraint on supply and price, independent of demand. Third, the product catalogue itself will keep expanding and reshuffling at the article level. A professional view has to monitor all three at once, and it has to do so from data that is maintained continuously rather than compiled once.
This content is intended for healthcare professionals and does not constitute medical advice. Last reviewed: July 2026.
